Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993159 · ClinicalTrials.gov registry record · Phase 2
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02993159 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 100 participants.
The verdict
NCT02993159, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Tamoxifen Citrate
- DRUG Afimoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2022-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993159
The ClinicalTrials.gov registry entry for NCT02993159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02993159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993159 about?
NCT02993159 is a clinical study titled "Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast". This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use...
What is the current status of trial NCT02993159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-05-31. Estimated completion is 2022-01-24.
What interventions are being tested in trial NCT02993159?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Tamoxifen Citrate (DRUG), Afimoxifene (DRUG).
Who is sponsoring clinical trial NCT02993159?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.